样式: 排序: IF: - GO 导出 标记为已读
-
Understanding network meta-analysis methodology for the ophthalmologist. Curr. Opin. Ophthalmol. (IF 3.7) Pub Date : 2024-03-15 Mark Phillips, Varun Chaudhary
Over the past decade, the number of studies published using network meta-analyses (NMAs) has rapidly increased, and there have been continued advancements to further advance this analysis approach. Due to the fast moving and changing landscape in the infancy of NMA methodology, there is a lack of consistency and standardization for this approach. This article aims to summarize the crucial components
-
New forays into measurement of ocular biomechanics. Curr. Opin. Ophthalmol. (IF 3.7) Pub Date : 2024-03-14 Emma Hammelef, Christopher J Rapuano, Dominick A Benedetto, Zeba A Syed, Jonathan S Myers, M Reza Razeghinejad, Fred H Silver, Jose S Pulido
The field of corneal biomechanics has rapidly progressed in recent years, reflecting technological advances and an increased understanding of the clinical significance of measuring these properties. This review will evaluate in-vivo biomechanical properties obtained by current technologies and compare them regarding their relevance to established biomechanical properties obtained by gold-standard ex-vivo
-
Systemic medications for sickle cell disease and potential applications for sickle cell retinopathy. Curr. Opin. Ophthalmol. (IF 3.7) Pub Date : 2024-03-11 Anupam K Garg, Adrienne W Scott
To review the literature evaluating systemic medications for treatment of sickle cell disease (SCD) and their applications for sickle cell retinopathy.
-
Gene therapy for age-related macular degeneration: potential, feasibility, and pitfalls. Curr. Opin. Ophthalmol. (IF 3.7) Pub Date : 2024-03-05 Sean T Berkowitz, Avni P Finn
The landscape for age-related macular degeneration (AMD) is rapidly changing with addition of biosimilars and now United States Food and Drug Administration (FDA) approved nonneovascular AMD (nnAMD) treatment options. These developments have inspired a burgeoning pipeline of gene therapy approaches focused on similar antivascular endothelial growth factors (VEGF) and complement related pathways. Historic
-
Geographic atrophy: current and future therapeutic agents and practical considerations for retinal specialists. Curr. Opin. Ophthalmol. (IF 3.7) Pub Date : 2024-02-29 Priya Vakharia, David Eichenbaum
Geographic atrophy (GA) from age-related macular degeneration (AMD) remains a leading cause of vision loss. The purpose of this review is to summarize currently available intravitreal therapeutics, and discuss pipeline therapeutics that are currently in clinical trials.
-
Retinal arterial and vein occlusion: is surgery ever indicated? Curr. Opin. Ophthalmol. (IF 3.7) Pub Date : 2024-02-29 Kazuaki Kadonosono, Maiko Inoue, Yasuo Yanagi
To highlight the recent progression in surgical treatments for central retinal vein occlusion (CRVO) and central retinal artery occlusion (CRAO).
-
Review and analysis of history and utilization of pneumatic retinopexy after pneumatic retinopexy versus vitrectomy for the management of primary rhegmatogenous retinal detachment outcomes randomized trial (PIVOT). Curr. Opin. Ophthalmol. (IF 3.7) Pub Date : 2024-02-16 Serena Shah, Brandon Chou, Marissa Patel, Arjun Watane, Lea Shah, Nicolas Yannuzzi, Jayanth Sridhar
We describe the history and series results of pneumatic retinopexy (PnR)and provide an analysis of PnR utilization after publication of results of pneumatic retinopexy versus vitrectomy for the management of primary rhegmatogenous retinal detachment outcomes randomized trial (PIVOT).
-
ChatGPT enters the room: what it means for patient counseling, physician education, academics, and disease management. Curr. Opin. Ophthalmol. (IF 3.7) Pub Date : 2024-02-08 Bita Momenaei, Hana A Mansour, Ajay E Kuriyan, David Xu, Jayanth Sridhar, Daniel S W Ting, Yoshihiro Yonekawa
This review seeks to provide a summary of the most recent research findings regarding the utilization of ChatGPT, an artificial intelligence (AI)-powered chatbot, in the field of ophthalmology in addition to exploring the limitations and ethical considerations associated with its application.
-
Enhanced durability and evolution of retreatment criteria of intravitreal antivascular endothelial growth factor agents for diabetic macular edema. Curr. Opin. Ophthalmol. (IF 3.7) Pub Date : 2024-02-01 Nikhil K Mandava, Ajay E Kuriyan, Allen C Ho, Jason Hsu, Carl D Regillo, Michael A Klufas
The increasing prevalence of diabetic macular edema (DME) necessitates an updated review of treatment modalities. While the shift from laser to anti-vascular endothelial growth factor (anti-VEGF) therapy has transformed patient outcomes, benefits of these agents are not fully realized in real-world implementation relative to the setting of controlled clinical trials. This review outlines the evolution
-
Weight loss, bariatric surgery, and novel antidiabetic drugs effects on diabetic retinopathy: a review. Curr. Opin. Ophthalmol. (IF 3.7) Pub Date : 2024-01-31 Alejandro M Perez, Emily Neag, Jayanth Sridhar, Basil K Williams
Diabetic retinopathy (DR) is a leading cause of visual impairment, and the increasing prevalence of diabetes and obesity will impact rates of visual impairment moving forward. Our review aims to synthesize the current body of evidence regarding the impact of lifestyle interventions, such as weight loss, bariatric surgery, and novel antidiabetic drugs, on DR.
-
Cell therapy for retinal disease. Curr. Opin. Ophthalmol. (IF 3.7) Pub Date : 2024-01-25 Goutham R Yalla, Ajay E Kuriyan
This review presents an update on completed stem cell therapy trials aimed at retinal diseases.
-
Applications of artificial intelligence-enabled robots and chatbots in ophthalmology: recent advances and future trends. Curr. Opin. Ophthalmol. (IF 3.7) Pub Date : 2024-01-23 Yeganeh Madadi, Mohammad Delsoz, Albert S Khouri, Michael Boland, Andrzej Grzybowski, Siamak Yousefi
Recent advances in artificial intelligence (AI), robotics, and chatbots have brought these technologies to the forefront of medicine, particularly ophthalmology. These technologies have been applied in diagnosis, prognosis, surgical operations, and patient-specific care in ophthalmology. It is thus both timely and pertinent to assess the existing landscape, recent advances, and trajectory of trends
-
Recent developments of telemedicine in glaucoma. Curr. Opin. Ophthalmol. (IF 3.7) Pub Date : 2024-01-19 Jason J Jo, Louis R Pasquale
Telemedicine has an increasingly significant role in the fields of ophthalmology and glaucoma. This review covers recent advancements in the development and optimization of teleglaucoma techniques and applications.
-
Implementation of optical coherence tomography in retinopathy of prematurity screening. Curr. Opin. Ophthalmol. (IF 3.7) Pub Date : 2024-01-12 Adam M Hanif, Yifan Jian, Benjamin K Young, John Peter Campbell
In this review, we explore the investigational applications of optical coherence tomography (OCT) in retinopathy of prematurity (ROP), the insights they have delivered thus far, and key milestones for its integration into the standard of care.
-
Intravitreal enzyme replacement for inherited retinal diseases. Curr. Opin. Ophthalmol. (IF 3.7) Pub Date : 2023-12-27 Ana Catalina Rodriguez-Martinez, James Wawrzynski, Robert H Henderson
This paper provides an update on intravitreal (IVT) enzyme replacement therapy (ERT) in metabolic retinal diseases; particularly neuronal ceroid lipofuscinosis type 2 (CLN2) also known as Batten disease.
-
Genes as drugs for glaucoma: latest advances. Curr. Opin. Ophthalmol. (IF 3.7) Pub Date : 2023-12-21 Teresa Borrás, Michelle Stepankoff, John Danias
To provide the latest advances on the future use of gene therapy for the treatment of glaucoma.
-
Leber hereditary optic neuropathy gene therapy. Curr. Opin. Ophthalmol. (IF 3.7) Pub Date : 2023-12-21 Byron L Lam
To discuss relevant clinical outcomes, challenges, and future opportunities of gene therapy in Leber hereditary optic neuropathy (LHON).
-
Glaucoma surgical procedures under development. Curr. Opin. Ophthalmol. (IF 3.7) Pub Date : 2023-12-15 Ariana M Levin, Arsham Sheybani
Rapid innovation in glaucoma surgery is expanding surgical options in the angle, subconjunctival space, and supraciliary space.
-
A review of posterior chamber phakic intraocular lenses. Curr. Opin. Ophthalmol. (IF 3.7) Pub Date : 2023-12-07 Dan Z Reinstein, Cheryl MacGregor, Timothy J Archer, Ruchi Gupta, Joseph G Potter
Posterior chamber phakic intraocular lenses (pIOLs) are increasing in popularity as a viable alternative to laser refractive surgery. The purpose of this review is to evaluate the recent updates to pIOLs and to assess the advancements and safety of the procedure.
-
How much does cataract surgery contribute to intraocular pressure lowering? Curr. Opin. Ophthalmol. (IF 3.7) Pub Date : 2023-11-30 Jasdeep Sabharwal, Anupam K Garg, Pradeep Y Ramulu
To review the literature evaluating the effect of cataract surgery on intraocular pressure (IOP) in patients with glaucoma.
-
Artificial intelligence for glaucoma: state of the art and future perspectives. Curr. Opin. Ophthalmol. (IF 3.7) Pub Date : 2023-11-30 Rafael Correia Barão, Ruben Hemelings, Luís Abegão Pinto, Marta Pazos, Ingeborg Stalmans
To address the current role of artificial intelligence (AI) in the field of glaucoma.
-
Impact of smoking on glaucoma. Curr. Opin. Ophthalmol. (IF 3.7) Pub Date : 2023-11-28 Golnoush Mahmoudinezhad, Leo Meller, Sasan Moghimi
Assessing whether lifestyle related factors play a role in causing primary open-angle glaucoma (POAG) is of great value to clinicians, public health experts and policy makers. Smoking is a major global public health concern and contributes to ocular diseases such as cataracts, and age-related macular degeneration through ischemic and oxidative mechanisms. Recently, smoking has been investigated as
-
Cataract surgery in setting of ocular surface disease. Curr. Opin. Ophthalmol. (IF 3.7) Pub Date : 2023-11-28 Enrica Sarnicola, Caterina Sarnicola, Maddalena De Bernardo, Nicola Rosa, Vincenzo Sarnicola
The purpose of this article is to review the available strategies to successfully identify and manage ocular surface disease (OSD) pre, intra and post-cataract surgery.
-
Refractive cataract surgery. Curr. Opin. Ophthalmol. (IF 3.7) Pub Date : 2023-11-14 Rhea Narang, Ashvin Agarwal
The aim of this study to provide an overview of recent publications and opinions in refractive cataract surgery.
-
Cataract surgery after corneal refractive surgery: preoperative considerations and management. Curr. Opin. Ophthalmol. (IF 3.7) Pub Date : 2023-11-14 Darren Sj Ting, Damien Gatinel, Marcus Ang
Corneal refractive surgery (CRS) is one of the most popular eye procedures, with more than 40 million cases performed globally. As CRS-treated patients age and develop cataract, the number of cases that require additional preoperative considerations and management will increase around the world. Thus, we provide an up-to-date, concise overview of the considerations and outcomes of cataract surgery
-
Future directions of glaucoma treatment: emerging gene, neuroprotection, nanomedicine, stem cell, and vascular therapies. Curr. Opin. Ophthalmol. (IF 3.7) Pub Date : 2023-11-02 Elizabeth C Ciociola,Elise Fernandez,Mary Kaufmann,Meredith R Klifto
PURPOSE OF REVIEW The aim of this article is to summarize current research on novel gene, stem cell, neuroprotective, nanomedicine, and vascular therapies for glaucoma. RECENT FINDINGS Gene therapy using viral vectors and siRNA have been shown to reduce intraocular pressure by altering outflow and production of aqueous humor, to reduce postsurgical fibrosis with few adverse effects, and to increase
-
Outcomes and predictive factors in multifocal and extended depth of focus intraocular lens implantation. Curr. Opin. Ophthalmol. (IF 3.7) Pub Date : 2023-11-02 Matthew De la Paz,Linda M Tsai
PURPOSE OF REVIEW Options for addressing presbyopia with intraocular lens (IOL) implantation have become more varied and sophisticated. We reviewed recent literature on multifocal and extended depth of focus (EDOF) IOLs in order to provide insight on their respective advantages, with emphasis on the visual outcomes of each design. RECENT FINDINGS Increased patient age, spectral domain optical coherence
-
Oxidative stress and antioxidants in cataract development. Curr. Opin. Ophthalmol. (IF 3.7) Pub Date : 2023-10-27 Bryanna Lee, Natalie A Afshari, Peter X Shaw
Oxidative stress plays a central role in cataract pathogenesis, a leading cause of global blindness. This review delves into the role of oxidative stress in cataract development and key biomarkers - glutathione (GSH), superoxide dismutase (SOD), malondialdehyde (MDA), and 4-hydroxynonenal (4-HNE) - to clarify their functions and potential applications in predictive diagnostics and therapies.
-
Intracameral antibiotics during cataract surgery: efficacy, safety, and cost-benefit considerations. Curr. Opin. Ophthalmol. (IF 3.7) Pub Date : 2023-10-26 Alexander C Lieu,Jong Hwa Jun,Natalie A Afshari
PURPOSE OF REVIEW We summarize evidence-based considerations regarding the use of intracameral antibiotics during cataract surgery. RECENT FINDINGS The use of intraoperative intracameral antibiotics reduced the incidence of postcataract surgery endophthalmitis 3.5-fold, with an odds ratio ranging from 0.14 to 0.19. A survey of the American Society of Cataract and Refractive Surgery showed usage of
-
Immediately sequential bilateral cataract surgery. Curr. Opin. Ophthalmol. (IF 3.7) Pub Date : 2023-10-19 Ali Nowrouzi, Jorge L Alió
This review aims to clarify the advantages and disadvantages of immediately sequential bilateral cataract surgery (ISBCS) based on recent studies, illustrate the safety of this approach, the cost-effectiveness, and present the importance of inclusion protocols for the best results.
-
Evidence-based management of optic neuritis. Curr. Opin. Ophthalmol. (IF 3.7) Pub Date : 2023-10-17 Emilie Bergeron, Marc A Bouffard
Optic neuritis can result from several distinct causes, including multiple sclerosis (MS), neuromyelitis optica spectrum disorder (NMOSD), and myelin oligodendrocyte glycoprotein antibody disease (MOGAD), when not idiopathic. This review discusses evidence-based treatment approaches contingent upon each specific cause of optic neuritis.
-
Ophthalmic manifestations of Whipple's disease. Curr. Opin. Ophthalmol. (IF 3.7) Pub Date : 2023-10-16 Nailyn Rasool
Whipple's disease is an infectious cause of uveitis that may present with nonspecific findings of intraocular inflammation, which can precede the development of neurologic symptoms and signs. Whipple's disease, then, may evade consideration in the differential diagnosis for uveitis.
-
An update on intraocular lens power calculations in eyes with previous laser refractive surgery. Curr. Opin. Ophthalmol. (IF 3.7) Pub Date : 2023-10-12 Daniel E Savage, Seth M Pantanelli
There is an ever-growing body of research regarding intraocular lens (IOL) power calculations following photorefractive keratectomy (PRK), laser-assisted in-situ keratomileusis (LASIK), and small-incision lenticule extraction (SMILE). This review intends to summarize recent data and offer updated recommendations.
-
Treatment of geographic atrophy: an update on data related to pegcetacoplan. Curr. Opin. Ophthalmol. (IF 3.7) Pub Date : 2023-10-11 Sagar B Patel, Jeffrey S Heier, Varun Chaudhary, Charles C Wykoff
Geographic atrophy is an advanced and currently untreatable form of age-related macular degeneration (AMD), which leads to significant compromise of visual function and quality of life. Dysregulation of the complement cascade has been directly implicated in AMD pathogenesis. Pegcetacoplan is a pegylated highly selective bicyclic peptide that inhibits the cleavage of complement component 3 (C3), which
-
Neuro-ophthalmic manifestations of autoimmune disorders: diagnostic pearls & pitfalls. Curr. Opin. Ophthalmol. (IF 3.7) Pub Date : 2023-09-20 Sabrina Poonja,Fiona Costello
PURPOSE OF REVIEW The purpose of this review is to highlight a clinical-anatomical approach to localizing neuro-ophthalmic manifestations of associated autoimmune disorders. RECENT FINDINGS Our understanding of autoimmune conditions has changed considerably over recent years, particularly with the emergence of novel autoantibodies. Cardinal neuro-ophthalmic signs and symptoms of antibody-mediated autoimmune
-
Anxiety and depression in patients with uveitis: a comprehensive review of observational studies. Curr. Opin. Ophthalmol. (IF 3.7) Pub Date : 2023-09-07 Charlene H Choo,John Gonzales,Jessica G Shantha
PURPOSE OF THE REVIEW The purpose of this review is to provide a comprehensive summary of observational studies evaluating anxiety and depression in patients with uveitis. RECENT FINDINGS A higher prevalence of depression was reported in patients with uveitis compared to healthy controls in most observational studies. Symptoms of anxiety were often, but not always, significantly worse in patients with
-
Challenges and controversies in ophthalmology in 2023. Curr. Opin. Ophthalmol. (IF 3.7) Pub Date : 2023-09-01 Christina Y Weng,Jayanth Sridhar
-
Insights into spaceflight-associated neuro-ocular syndrome with review of intraocular and orbital findings. Curr. Opin. Ophthalmol. (IF 3.7) Pub Date : 2023-08-30 Dallin C Milner,Prem S Subramanian
PURPOSE OF REVIEW Spaceflight-associated neuro-ocular syndrome (SANS) remains a phenomenological term, and advances in ophthalmic imaging as well as new insights from ground-based experiments have given support to new theories of how SANS develops and what may be done to counter it. RECENT FINDINGS SANS has been postulated to arise from elevated intracranial pressure (ICP) during long-duration spaceflight
-
Efficacy of teprotumumab therapy in patients with long-duration thyroid eye disease. Curr. Opin. Ophthalmol. (IF 3.7) Pub Date : 2023-08-24 Prem S Subramanian, Raymond I Cho, Alon Kahana
Teprotumumab, an inhibitor of the insulin-like growth factor 1 receptor (IGF-1R), was approved by the US Food and Drug Administration in January 2020 for the treatment of thyroid eye disease (TED). The clinical trials leading to its approval enrolled patients with recent disease onset and significant inflammatory symptoms and signs. Subsequent real-world teprotumumab use in patients with longer duration
-
Novel approach to Behçet's disease in the era of biologic agents. Curr. Opin. Ophthalmol. (IF 3.7) Pub Date : 2023-08-24 Chansathya Khieu, David Chanthan
This review aims to provide better understanding of modern modalities to investigate ocular symptoms of Behçet's disease in order to achieve appropriate management protocols and reduce irreversible visual loss.
-
Linezolid optic neuropathy. Curr. Opin. Ophthalmol. (IF 3.7) Pub Date : 2023-08-22 H Victoria Miller, Angela A Cao, Collin M McClelland, Michael S Lee
In this article, we reviewed 67 reported cases of linezolid optic neuropathy and describe the common characteristics and expectations for recovery with an emphasis on recent findings in the literature.
-
Opsoclonus and ocular flutter: evaluation and management. Curr. Opin. Ophthalmol. (IF 3.7) Pub Date : 2023-08-22 Scott N Grossman, Janet C Rucker
Opsoclonus and ocular flutter are saccadic intrusions characterized by spontaneous, back-to-back, fast eye movements (saccades) that oscillate about the midline of central visual fixation without intervening inter-saccadic intervals. When this type of movement occurs exclusively in the horizontal plane, it is called ocular flutter. When it occurs in multiple planes (i.e. horizontal, vertical, and torsional)
-
Neuro-ophthalmic complications of varicella-zoster virus. Curr. Opin. Ophthalmol. (IF 3.7) Pub Date : 2023-08-22 Toluwalase O Tofade, Bart K Chwalisz
This review broadly describes recent neuro-ophthalmic manifestations of varicella-zoster virus (VZV) reported in literature.
-
Ophthalmic manifestations of tuberculosis. Curr. Opin. Ophthalmol. (IF 3.7) Pub Date : 2023-08-21 Brandon Bates, Eric L Crowell
To evaluate the epidemiology, microbiology, and pathology of Mycobacterium Tuberculosis (MTB). Utilizing these basic science concepts, the reader will discover how MTB can cause disease in any part of ophthalmic system. This article will aid clinicians in establishing the difficult diagnosis and management strategies for ophthalmic tuberculosis (OTB).
-
Ocular features in Williams-Beuren syndrome: a review of the literature. Curr. Opin. Ophthalmol. (IF 3.7) Pub Date : 2023-08-17 Marco Nassisi,Claudia Mainetti,Andrea Aretti,Andrea Sperti,Valeria Nicotra,Berardo Rinaldi,Federica Natacci,Maria Francesca Bedeschi,Francesco Viola
PURPOSE OF REVIEW The current review will discuss the pathophysiology, work-up and clinical relevance of the ocular phenotype in Williams-Beuren syndrome in detail. RECENT FINDINGS Few case reports, case series and retrospective studies reported the ophthalmic features in Williams-Beuren syndrome, focusing on specific aspects of the ocular involvement. Recently, novel retinal findings have been described
-
Posterior segment manifestations of ocular metastasis. Curr. Opin. Ophthalmol. (IF 3.7) Pub Date : 2023-08-09 Wijak Kongwattananon,Thananop Pothikamjorn,Thanapong Somkijrungroj
PURPOSE OF REVIEW This article reviewed and summarized recent published data on ocular imaging findings and treatment of posterior segment manifestations of ocular metastasis. RECENT FINDINGS Advanced ocular imaging can help differentiate ocular metastases from other mimicking lesions, including primary intraocular tumors or infections. Recently, case reports have demonstrated the successful use of
-
Recent evidence of economic evaluation of artificial intelligence in ophthalmology. Curr. Opin. Ophthalmol. (IF 3.7) Pub Date : 2023-07-18 Paisan Ruamviboonsuk, Varis Ruamviboonsuk, Richa Tiwari
Health economic evaluation (HEE) is essential for assessing value of health interventions, including artificial intelligence. Recent approaches, current challenges, and future directions of HEE of artificial intelligence in ophthalmology are reviewed.
-
Gaps and future of human-centered artificial intelligence in ophthalmology: Future Vision Forum consensus statement. Curr. Opin. Ophthalmol. (IF 3.7) Pub Date : 2023-07-18 Daniel Shu Wei Ting, Mark S Humayun, Suber S Huang
The Future Vision Forum discussed the current state of Human Centered Computing and the future of data collection, curation, and collation in ophthalmology. Although the uptake of electronic health record (EHR) systems and the digitization of healthcare data is encouraging, there are still barriers to implementing a specialty-wide clinical trial database. The article identifies several critical opportunities
-
Toward safer ophthalmic artificial intelligence via distributed validation on real-world data. Curr. Opin. Ophthalmol. (IF 3.7) Pub Date : 2023-07-18 Siddharth Nath, Ehsan Rahimy, Ashley Kras, Edward Korot
The current article provides an overview of the present approaches to algorithm validation, which are variable and largely self-determined, as well as solutions to address inadequacies.
-
Explainable artificial intelligence in ophthalmology. Curr. Opin. Ophthalmol. (IF 3.7) Pub Date : 2023-07-03 Ting Fang Tan, Peilun Dai, Xiaoman Zhang, Liyuan Jin, Stanley Poh, Dylan Hong, Joshua Lim, Gilbert Lim, Zhen Ling Teo, Nan Liu, Daniel Shu Wei Ting
Despite the growing scope of artificial intelligence (AI) and deep learning (DL) applications in the field of ophthalmology, most have yet to reach clinical adoption. Beyond model performance metrics, there has been an increasing emphasis on the need for explainability of proposed DL models.
-
Artificial intelligence enabled smart digital eye wearables. Curr. Opin. Ophthalmol. (IF 3.7) Pub Date : 2023-06-29 Narrendar RaviChandran, Zhen Ling Teo, Daniel S W Ting
Smart eyewear is a head-worn wearable device that is evolving as the next phase of ubiquitous wearables. Although their applications in healthcare are being explored, they have the potential to revolutionize teleophthalmology care. This review highlights their applications in ophthalmology care and discusses future scope.
-
Alternative career paths for ophthalmologists. Curr. Opin. Ophthalmol. (IF 3.7) Pub Date : 2023-06-20 Natalia F Callaway, Emmett T Cunningham
Traditionally, ophthalmologists complete training and then choose a clinical care setting. The skills required to become an ophthalmologist can be applied to a variety of alternative career paths within and beyond healthcare. Not unexpectedly, therefore, there is a growing trend for ophthalmologists to explore alternative career paths in both healthcare and the life science industry more broadly. In
-
Artificial intelligence for home monitoring devices. Curr. Opin. Ophthalmol. (IF 3.7) Pub Date : 2023-06-20 Tiarnan D L Keenan, Anat Loewenstein
Home monitoring in ophthalmology is appropriate for disease stages requiring frequent monitoring or rapid intervention, for example, neovascular age-related macular degeneration (AMD) and glaucoma, where the balance between frequent hospital attendance versus risk of late detection is a constant challenge. Artificial intelligence approaches are well suited to address some challenges of home monitoring
-
Artificial intelligence for ocular oncology. Curr. Opin. Ophthalmol. (IF 3.7) Pub Date : 2023-06-20 Neslihan Dilruba Koseoglu, Zélia Maria Corrêa, T Y Alvin Liu
The aim of this article is to provide an update on the latest applications of deep learning (DL) and classical machine learning (ML) techniques to the detection and prognostication of intraocular and ocular surface malignancies.
-
The impact of artificial intelligence on retinal disease management: Vision Academy retinal expert consensus. Curr. Opin. Ophthalmol. (IF 3.7) Pub Date : 2023-06-19 Carla Danese, Aditya U Kale, Tariq Aslam, Jane Barratt, Yu-Bai Chou, Bora Eldem, Nicole Eter, Richard Gale, Jean-François Korobelnik, Igor Kozak, Paolo Lanzetta, Xiaorong Li, Xiaoxin Li, Anat Loewenstein, Paisan Ruamviboonsuk, Taiji Sakamoto, Daniel S W Ting, Peter van Wijngaarden, Sebastian M Waldstein, David Wong, Lihteh Wu, Miguel A Zapata, Javier Zarranz-Ventura
The aim of this review is to define the "state-of-the-art" in artificial intelligence (AI)-enabled devices that support the management of retinal conditions and to provide Vision Academy recommendations on the topic.
-
Current status and practical considerations of artificial intelligence use in screening and diagnosing retinal diseases: Vision Academy retinal expert consensus. Curr. Opin. Ophthalmol. (IF 3.7) Pub Date : 2023-06-16 Yu-Bai Chou, Aditya U Kale, Paolo Lanzetta, Tariq Aslam, Jane Barratt, Carla Danese, Bora Eldem, Nicole Eter, Richard Gale, Jean-François Korobelnik, Igor Kozak, Xiaorong Li, Xiaoxin Li, Anat Loewenstein, Paisan Ruamviboonsuk, Taiji Sakamoto, Daniel S W Ting, Peter van Wijngaarden, Sebastian M Waldstein, David Wong, Lihteh Wu, Miguel A Zapata, Javier Zarranz-Ventura
The application of artificial intelligence (AI) technologies in screening and diagnosing retinal diseases may play an important role in telemedicine and has potential to shape modern healthcare ecosystems, including within ophthalmology.
-
Revisiting the past for the future of refractive surgery. Curr. Opin. Ophthalmol. (IF 3.7) Pub Date : 2023-07-01 Jimmy K Lee
-
Private equity in ophthalmology: taking the long view. Curr. Opin. Ophthalmol. (IF 3.7) Pub Date : 2023-05-24 Jane M Zhu, Christopher M Aderman
Private equity's momentum in eye care remains controversial, even as investment continues to hasten the consolidation of ophthalmology and optometry practices. In this review, we discuss the growing implications of private equity activity in ophthalmology, drawing on updated empirical findings from the literature. We also examine recent legal and policy efforts to address private equity investment
-
Refractive lens exchange - who is getting it, what are they getting, how are they doing? Curr. Opin. Ophthalmol. (IF 3.7) Pub Date : 2023-05-15 Lauren F Ong,Alyce Oh,Joseph K Yi,Joshua S Gu,Amir H Marvasti,Betsy B Nguyen,Dan B Tran,Jimmy K Lee
PURPOSE OF REVIEW The purpose of this article is to provide a review of the literature on refractive lens exchange and present a retrospective analysis of 55 patients who underwent refractive lens exchange at a single practice. RECENT FINDINGS Our study substantiates refractive lens exchange as an important option for presbyopic patients, hyperopic patients or patients with extremely high refractive
-
Safety of recent ophthalmic drugs and devices for wet macular degeneration. Curr. Opin. Ophthalmol. (IF 3.7) Pub Date : 2023-05-04 Elise Timtim, Christina Y Weng, Avni P Finn
With frequent antivascular endothelial growth factors (VEGF) injections well established as the standard of care in neovascular age-related macular degeneration (nAMD), focus has now shifted towards decreasing treatment burden without compromising safety and efficacy. This review summarizes clinical stage and recently approved drugs and devices for nAMD, with an emphasis paid to safety concerns and